{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:34:27Z","timestamp":1789749267742,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T00:00:00Z","timestamp":1378771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40263-013-0110-x","type":"journal-article","created":{"date-parts":[[2013,9,9]],"date-time":"2013-09-09T03:29:36Z","timestamp":1378697376000},"page":"851-861","source":"Crossref","is-referenced-by-count":68,"title":["Extended-Release Intramuscular Naltrexone (VIVITROL\u00ae): A Review of Its Use in the Prevention of Relapse to Opioid Dependence in Detoxified Patients"],"prefix":"10.1007","volume":"27","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian M.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,10]]},"reference":[{"issue":"2","key":"110_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11597520-000000000-00000","volume":"72","author":"JM Tetrault","year":"2012","unstructured":"Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217\u201328.","journal-title":"Drugs."},{"key":"110_CR2","unstructured":"Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-44, HHS publication no. (SMA) 12-4713. Rockville: Substance Abuse and Mental Health Services Administration; 2012."},{"issue":"4","key":"110_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367.","journal-title":"Pain Med."},{"key":"110_CR4","unstructured":"World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. http:\/\/www.who.int\/substance_abuse\/publications\/opioid_dependence_guidelines.pdf . Accessed 22 May 2013."},{"key":"110_CR5","unstructured":"Substance Abuse and Mental Health Services Administration. SAMHSA Advisory: an introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. 2012. http:\/\/store.samhsa.gov\/shin\/content\/\/SMA12-4682\/SMA12-4682.pdf . Accessed 7 Mar 2013."},{"issue":"9719","key":"110_CR6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","volume":"375","author":"BM Mathers","year":"2010","unstructured":"Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014\u201328.","journal-title":"Lancet."},{"issue":"9","key":"110_CR7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/j.1360-0443.2010.03015.x","volume":"105","author":"MJ Fishman","year":"2010","unstructured":"Fishman MJ, Winstanley EL, Curran E, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1669\u201376.","journal-title":"Addiction."},{"issue":"9776","key":"110_CR8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","volume":"377","author":"E Krupitsky","year":"2011","unstructured":"Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506\u201313.","journal-title":"Lancet."},{"issue":"2","key":"110_CR9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210\u20138.","journal-title":"Arch Gen Psychiatry."},{"issue":"8","key":"110_CR10","first-page":"835","volume":"5","author":"V Modesto-Lowe","year":"2002","unstructured":"Modesto-Lowe V. Naltrexone depot DrugAbuse sciences. IDrugs. 2002;5(8):835\u20138.","journal-title":"IDrugs."},{"issue":"3","key":"110_CR11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1530-0277.2006.00052.x","volume":"30","author":"JL Dunbar","year":"2006","unstructured":"Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480\u201390.","journal-title":"Alcohol Clin Exp Res."},{"issue":"11","key":"110_CR12","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","volume":"28","author":"RT Bartus","year":"2003","unstructured":"Bartus RT, Emerich DF, Hotz J, et al. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology. 2003;28(11):1973\u201382.","journal-title":"Neuropsychopharmacology."},{"key":"110_CR13","unstructured":"Alkermes Inc. VIVITROL\u00ae (naltrexone for extended-release injectable suspension), intramuscular: prescribing information. 2010. http:\/\/www.vivitrol.com\/Content\/pdf\/prescribing_info.pdf . Accessed 20 Feb 2013."},{"key":"110_CR14","unstructured":"Alkermes Inc. Annual report on form 10-K for the fiscal year ended March 31, 2012. 2012. http:\/\/www.sec.gov\/Archives\/edgar\/data\/1520262\/000104746912006168\/a2209642z10-k.htm . Accessed 21 Feb 2013."},{"issue":"13","key":"110_CR15","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.2165\/00003495-200666130-00006","volume":"66","author":"T Swainston Harrison","year":"2006","unstructured":"Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs. 2006;66(13):1741\u201351.","journal-title":"Drugs."},{"issue":"3","key":"110_CR16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","volume":"35","author":"JP Gonzalez","year":"1988","unstructured":"Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192\u2013213.","journal-title":"Drugs."},{"issue":"1\u20133","key":"110_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","volume":"123","author":"GE Bigelow","year":"2012","unstructured":"Bigelow GE, Preston KL, Schmittner J, et al. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend. 2012;123(1\u20133):57\u201365.","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"110_CR18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0091270005280199","volume":"45","author":"RZ Turncliff","year":"2005","unstructured":"Turncliff RZ, Dunbar JL, Dong Q, et al. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45(11):1259\u201367.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"110_CR19","doi-asserted-by":"crossref","first-page":"862","DOI":"10.15288\/jsad.2007.68.862","volume":"68","author":"JL Dunbar","year":"2007","unstructured":"Dunbar JL, Turncliff RZ, Hayes SC, et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs. 2007;68(6):862\u201370.","journal-title":"J Stud Alcohol Drugs."},{"key":"110_CR20","author":"E Krupitsky","year":"2013","unstructured":"Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;. doi: 10.1111\/add.12208 .","journal-title":"Addiction."},{"key":"110_CR21","unstructured":"Earley PH, Gastfriend D, Memisoglu A, et al. Open-label study of intramuscular extended-release naltrexone (XR-NTX) in healthcare professional with opioid dependence [abstract no. NR7-11]. 165th Annual Meeting of the American Psychiatric Association; 5\u20139 May 2012; Philadelphia, PA."},{"key":"110_CR22","unstructured":"Lee J, Selling D, McDonald R, et al. Extended-release naltrexone (medical management in primary care and) criminal justice settings [oral presentation]. 74th Annual Meeting\u2014College on Problems of Drug Dependence; Jun 9\u201314 2012; Palm Springs, CA."},{"key":"110_CR23","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"issue":"12","key":"110_CR24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.293.12.1513","volume":"293","author":"DR Gastfriend","year":"2005","unstructured":"Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians-and everyone else? JAMA. 2005;293(12):1513\u20135.","journal-title":"JAMA."},{"issue":"6","key":"110_CR25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.15288\/jsad.2012.73.991","volume":"73","author":"MC Mitchell","year":"2012","unstructured":"Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73(6):991\u20137.","journal-title":"J Stud Alcohol Drugs."},{"key":"110_CR26","unstructured":"Alkermes Inc. Medication guide: VIVITROL\u00ae (naltrexone for extended-release injectable suspension). 2013. http:\/\/www.vivitrol.com\/Content\/pdf\/medication_guide.pdf . Accessed 22 May 2013."},{"issue":"Suppl 8","key":"110_CR27","first-page":"S235","volume":"17","author":"O Baser","year":"2011","unstructured":"Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235\u201348.","journal-title":"Am J Manag Care."},{"key":"110_CR28","unstructured":"National Institute on Drug Abuse. Extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT). 2013. http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0051.htm . Accessed 8 Mar 2013."},{"key":"110_CR29","unstructured":"Silverman B, Gastfriend DR. Safety and effectiveness of treatment with a once-monthly, injectable formulation of naltrexone (XR-NTX) in a real-world clinical practice setting [abstract no. NR7-10]. 165th Annual Meeting of the American Psychiatric Association; 5\u20139 May 2012; Philadelphia, PA."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0110-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0110-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0110-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:18Z","timestamp":1559490078000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0110-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0110-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,10]]}}}